Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1593-1600

  Ota, Ichiro ^a   Higashiyama, Shigeki ^b   Masui, Takashi ^a   Yane, Katsunari ^c   Hosoi, Hiroshi ^a   Matsuura, Nariaki ^d  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Heparin binding EGF like growth factor; Invasion and metastasis; Thyroid cancer

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID HYPERPLASIA; THYROID PAPILLARY CARCINOMA; TUMOR INVASION; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTAXIS; DIPHTHERIA TOXIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; THYROID NEOPLASMS; TYRPHOSTINS;

EID: 84882617689     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2659     Document Type: Article

References (51)

1. Ito Y, Hirokawa M, Kihara M, et al: Prognostic value of poorly differentiated carcinoma in Japanese Society of Thyroid Surgery in a series of papillary thyroid carcinoma patients: comparison with risk classification system in Kuma Hospital. Endocr J 59: 817-821, 2012.
2. Xing M: Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20: 697-706, 2010.
3. Stoscheck CM and King LE Jr: Role of epidermal growth factor in carcinogenesis. Cancer Res 46: 1030-1037, 1986.
4. Higashiyama S, Abraham JA, Miller J, Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991.
5. Raab G, Higashiyama S, Hetelekidis S, et al: Biosynthesis and processing by phorbol ester of the cells surface-associated precursor form of heparin-binding EGF-like growth factor. Biochem Biophys Res Commun 204: 592-597, 1994.
6. Besner G, Higashiyama S and Klagsbrun M: Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell Regul 1: 811-819, 1990.
7. Higashiyama S, Lau K, Besner GE, Abraham JA and Klagsbrun M: Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 267: 6205-6212, 1992.
8. Higashiyama S, Abraham JA and Klagsbrun M: Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 122: 933-940, 1993.
9. Marikovsky M, Breuing K, Liu PY, et al: Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 90: 3889-3893, 1993.
10. Hashimoto K, Higashiyama S, Asada H, et al: Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 269: 20060-20066, 1994.
11. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M and Eberlein TJ: T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 92: 6547-6551, 1995.
12. Miyagawa J, Higashiyama S, Kawata S, et al: Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 95: 404-411, 1995.
13. Powell PP, Klagsbrun M, Abraham JA and Jones RC: Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension. Am J Pathol 143: 784-793, 1993.
14. Mangrulkar RS, Ono M, Ishikawa M, Takashima S, Klagsbrun M and Nowak RA: Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 53: 636-646, 1995.
15. Higashiyama S, Iwamoto R, Goishi K, et al: The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 128: 929-938, 1995.
16. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M and Mekada E: Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 13: 2322-2330, 1994.
17. Yotsumoto F, Yagi H, Suzuki SO, et al: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561, 2008.
18. Miyamoto S, Hirata M, Yamazaki A, et al: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727, 2004.
19. Inui Y, Higashiyama S, Kawata S, et al: Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 107: 1799-1804, 1994.
20. Naef M, Yokoyama M, Friess H, Buchler MW and Korc M: Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 66: 315-321, 1996.
21. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P and Korc M: Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202: 1705-1709, 1994.
22. Ohnishi Y, Inoue H, Furukawa M, Kakudo K and Nozaki M: Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma. Oncol Rep 27: 954-958, 2012.
23. Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR: Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res 56: 1184-1188, 1996.
24. Elenius K, Paul S, Allison G, Sun J and Klagsbrun M: Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16: 1268-1278, 1997.
25. Ito T, Seyama T, Mizuno T, et al: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369-1371, 1992.
26. Fogh J, Wright WC and Loveless JD: Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-214, 1977.
27. Sobin LH and Wittekind C (eds): International Union against Cancer. TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss, New York, NY, 2002.
28. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44: 1299-1305, 1997.
29. Boyden S: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115: 453-466, 1962.
30. Yoshida A, Anand-Apte B and Zetter BR: Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 13: 57-64, 1996.
31. Goodman SL, Vollmers HP and Birchmeier W: Control of cell locomotion: perturbation with an antibody directed against specific glycoproteins. Cell 41: 1029-1038, 1985.
32. Mannino RJ, Ballmer K, Zeltner D and Burger MM: An inhibitor of animal cell growth increases cell-to-cell adhesion. J Cell Biol 91: 855-859, 1981.
33. Giancotti FG and Ruoslahti E: Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60: 849-859, 1990.
34. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
35. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH and Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12: 475-482, 1994.
36. Noguchi S, Aihara T, Nakamori S, et al: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 74: 1595-1600, 1994.
37. Haugen DR, Akslen LA, Varhaug JE and Lillehaug JR: Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int J Cancer 55: 37-43, 1993.
38. Gorgoulis V, Aninos D, Priftis C, et al: Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors. In Vivo 6: 291-296, 1992.
39. Aasland R, Akslen LA, Varhaug JE and Lillehaug JR: Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int J Cancer 46: 382-387, 1990.
40. Freeman MR, Paul S, Kaefer M, et al: Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 68: 328-338, 1998.
41. Holting T, Siperstein AE, Clark OH and Duh QY: Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132: 229-235, 1995.
42. Ongusaha PP, Kwak JC, Zwible AJ, et al: HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64: 5283-5290, 2004.
43. Miyoshi E, Higashiyama S, Nakagawa T, Hayashi N and Taniguchi N: Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line. J Biol Chem 272: 14349-14355, 1997.
44. Shah JP, Loree TR, Dharker D, Strong EW, Begg C and Vlamis V: Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164: 658-661, 1992.
45. Suzuki M, Raab G, Moses MA, Fernandez CA and Klagsbrun M: Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272: 31730-31737, 1997.
46. Izumi Y, Hirata M, Hasuwa H, et al: A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17: 7260-7272, 1998.
47. Koshikawa N, Mizushima H, Minegishi T, et al: Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci 102: 111-116, 2010.
48. Nakamura H, Ueno H, Yamashita K, et al: Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 59: 467-473, 1999.
49. Aust G, Hofmann A, Laue S, Rost A, Kohler T and Scherbaum WA: Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein. Thyroid 7: 713-724, 1997.
50. Hofmann A, Laue S, Rost AK, Scherbaum WA and Aust G: mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid 8: 203-214, 1998.
51. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H and Matsushita N: Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 99: 214-220, 2008.